Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 105, Issue 6, Pages 1338-1344Publisher
WILEY
DOI: 10.1002/cpt.1319
Keywords
-
Categories
Funding
- National Institutes of Health (NIH) [R24GM115264, R24GM61374, R01AR053349]
- Intramural Research Program of the National Human Genome Research Institute
- NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG200359] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The identification in a patient of 1 of the 50 variants in the RYR1 or CACNA1S genes reviewed here should lead to a presumption of malignant hyperthermia susceptibility (MHS). MHS can lead to life-threatening reactions to potent volatile anesthetic agents or succinylcholine. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for the use of these agents in patients with these RYR1 or CACNA1S variants (updates at and ).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
